NCT05994378View on ClinicalTrials.gov

To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects

PHASE3CompletedINTERVENTIONAL
Enrollment

317

Participants

Timeline

Start Date

August 29, 2023

Primary Completion Date

May 2, 2025

Study Completion Date

May 2, 2025

Conditions
Infertile Female Subjects Undergoing Controlled Ovarian Hyperstimulation to Suppress Premature LH Surge and Prevent Early Ovulation
Interventions
DRUG

SHR7280；Ganirelix Acetate Injection simulant

SHR7280 200mg Q12h and Ganirelix Acetate Injection simulant 0.5mL qd;

DRUG

SHR7280 simulant； Ganirelix Acetate Injection

SHR7280 simulant 200mg Q12h and Ganirelix Acetate Injection 0.5mL:0.25mg qd;

Trial Locations (1)

100191

Peking University Third Hospital, Beijing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05994378 - To Compare the Efficacy and Safety of Oral SHR 7280 Tablets With Ganirelix Acetate Injection in Infertile Female Subjects | Biotech Hunter | Biotech Hunter